Fig. 4From: A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseChange in % predicted MIP at week 72. Individual subject change from baseline after receiving 20Â mg/kg reveglucosidase alfa intravenously every 2Â weeks. Abbreviation: MIP, maximal inspiratory pressureBack to article page